Tango Therapeutics Inc stock is traded at $23.18, with a volume of 2,465,972. It is up +0.04% in the last 24 hours and down -0.26% over the past month. Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Previous Close:
$23.17
Open:
$24.16
24h Volume:
2,465,972
Relative Volume:
0.48
Market Cap:
$3.91B
Revenue:
$56.99M
Net Income/Loss:
-$107.23M
P/E Ratio:
-
EPS:
-$0.8199
Net Cash Flow:
-$142.55M
1W Performance:
+4.27%
1M Performance:
-0.26%
6M Performance:
+2.07%
1Y Performance:
+189.39%
1-Day Range:
$22.67$24.75
1-Week Range:
$21.71$24.75
52-Week Range:
$7.37$34.39
Tango Therapeutics Inc Stock (TNGX) Company Profile
Name
Tango Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
(857) 320-4900Address
201 BROOKLINE AVENUE, BOSTON, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS